Dysregulated biomarkers of innate and adaptive immunity predict infections and disease progression in cirrhosis

被引:14
|
作者
Simbrunner, Benedikt [1 ,2 ,3 ,4 ,5 ]
Hartl, Lukas [1 ,2 ]
Jachs, Mathias [1 ,2 ]
Bauer, David J. M. [1 ,2 ]
Scheiner, Bernhard [1 ,2 ]
Hofer, Benedikt Silvester [1 ,2 ,3 ]
Staettermayer, Albert Friedrich [1 ,2 ]
Marculescu, Rodrig [6 ]
Trauner, Michael [1 ]
Mandorfer, Mattias [1 ,2 ]
Reiberger, Thomas [1 ,2 ,3 ,4 ,5 ]
机构
[1] Med Univ Vienna, Dept Med 3, Div Gastroenterol & Hepatol, Waehringer Guertel 18-20, A-1090 Vienna, Austria
[2] Med Univ Vienna, Dept Med 3, Div Gastroenterol & Hepatol, Vienna Hepat Hemodynam Lab, Vienna, Austria
[3] Med Univ Vienna, Christian Doppler Lab Portal Hypertens & Liver Fib, Vienna, Austria
[4] Ludwig Boltzmann Inst Rare & Undiagnosed Dis LBI R, Vienna, Austria
[5] Austrian Acad Sci, CeMM Res Ctr Mol Med, Vienna, Austria
[6] Med Univ Vienna, Dept Lab Med, Vienna, Austria
关键词
ACLD; Portal hypertension; Gut-liver axis; Immune dysfunction; ASCITIC FLUID; DECOMPENSATED CIRRHOSIS; BACTERIAL TRANSLOCATION; COMPLEMENT-SYSTEM; B-CELLS; LIVER; SERUM; INFLAMMATION; ACTIVATION; IGG;
D O I
10.1016/j.jhepr.2023.100712
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background & Aims: Cirrhosis-associated immune dysfunction (CAID) affects both innate and adaptive immunity. This study investigated the complement system, immunoglobulins, and acute-phase proteins and their prognostic relevance in patients with advanced chronic liver disease (ACLD).Methods: Patients with ACLD (hepatic venous pressure gradient [HVPG] >-6 mmHg) but without acute decompensation/in-fections were characterised by HVPG and by clinical EASL stages: compensated (cACLD; S0-2) vs. decompensated ACLD (dACLD) with previous variceal bleeding (S3), non-bleeding decompensation (S4), or further decompensation (S5). Com-plement factors (C3c, C4, CH50), immunoglobulins (IgA, IgM, IgG, IgG1-4), acute-phase proteins and systemic inflammation biomarkers (white blood cells, C-reactive protein, IL-6, procalcitonin) were measured.Results: A total of 245 patients (median model for end-stage liver disease score: 11 [9-15], median HVPG: 17 [12-21] mmHg) were included with 150 (61%) presenting dACLD. Complement levels and activity significantly decreased in dACLD substages S4 and S5 (p <0.001). Total IgA/IgM/IgG and IgG1-4 subtype levels increased in patients with dACLD (all p <0.05). Complement and immunoglobulin levels correlated negatively and positively, respectively, with systemic inflammation (all p <0.05). High IgG-1 (adjusted hazard ratio per 100 mg/dl: 1.12, 1.04-1.19, p = 0.002) and IL-6 (adjusted hazard ratio: 1.03, 1.00-1.05, p = 0.023) levels predicted the development of infections during follow-up. High IgA (stratified by median; log-rank p <0.001), high IgG1 (log-rank p = 0.043) and low C3c (log-rank p = 0.003) indicated a higher risk of first/further decompensation or liver-related death (composite endpoint). Next to HVPG and IL-6, low C3c (adjusted hazard ratio per mg/dl: 0.99, 0.97-0.99, p = 0.040) remained independently associated with the composite endpoint on multivariate Cox regression analysis.Conclusions: Complement levels and immunoglobulins may serve as surrogates of cirrhosis-associated immune dysfunction and associate with cirrhosis severity and systemic inflammation. Low complement C3c predicted decompensation and liver -related death, whereas high IgG-1 indicated an increased risk for infections.Impact and Implications: Patients with cirrhosis are at increased risk for infections, which worsen their prognosis. We found a significant dysregulation of several essential components of the immune system that was linked to disease severity and indicated a risk for infections and other complications. Simple blood tests identify patients at particularly high risk, who may be candidates for preventive measures.Clinical Trials Registration: This study is registered at ClinicalTrials.gov (NCT03267615).& COPY; 2023 The Authors. Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL). This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
引用
收藏
页数:11
相关论文
共 50 条
  • [1] Innate and adaptive immunity in viral infections
    Zeromski, Jan
    Mozer-Lisewska, Iwona
    Kowala-Piaskowska, Arleta
    CENTRAL EUROPEAN JOURNAL OF IMMUNOLOGY, 2011, 36 (04) : 298 - 302
  • [2] New Biomarkers of Innate and Adaptive Immunity in Infectious Diseases
    Morzunov, Sergey
    Deyde, Varough
    Abrahamyan, Levon
    JOURNAL OF IMMUNOLOGY RESEARCH, 2017, 2017
  • [3] Innate and adaptive immunity in neurodegenerative disease
    Huang, Yeyu
    Zhang, Guoxin
    Li, Sheng
    Feng, Jin
    Zhang, Zhentao
    CELLULAR AND MOLECULAR LIFE SCIENCES, 2025, 82 (01)
  • [4] Innate and adaptive immunity in celiac disease
    Anderson, Robert P.
    CURRENT OPINION IN GASTROENTEROLOGY, 2020, 36 (06) : 470 - 478
  • [5] Innate immunity and adaptive immunity in Crohn's disease
    Dai, Cong
    Jiang, Min
    Sun, Ming-Jun
    ANNALS OF TRANSLATIONAL MEDICINE, 2015, 3 (03)
  • [6] Innate and adaptive immunity in Candida albicans infections and saprophytism
    Romani, L
    JOURNAL OF LEUKOCYTE BIOLOGY, 2000, 68 (02) : 175 - 179
  • [7] A shift from adaptive to innate immunity: a potential mechanism of disease progression in multiple sclerosis
    Weiner, Howard L.
    JOURNAL OF NEUROLOGY, 2008, 255 (Suppl 1) : 3 - 11
  • [8] Innate and adaptive immunity in long-term non-progression in HIV disease
    Zaunders, John
    van Bockel, David
    FRONTIERS IN IMMUNOLOGY, 2013, 4
  • [9] A shift from adaptive to innate immunity: a potential mechanism of disease progression in multiple sclerosis
    Howard L. Weiner
    Journal of Neurology, 2008, 255 : 3 - 11
  • [10] Innate and adaptive immunity in inflammatory bowel disease
    Geremia, Alessandra
    Biancheri, Paolo
    Allan, Philip
    Corazza, Gino R.
    Di Sabatino, Antonio
    AUTOIMMUNITY REVIEWS, 2014, 13 (01) : 3 - 10